But results come from a curated dataset, with no in-trial comparator.
ApexOnco Front Page
Recent articles
Global data are in the same ballpark as Chinese results presented earlier this year.
The Tang Capital Partners vehicle has already acquired IGM, Elevation and Kronos.
The company, apparently unbothered by Enhertu, is starting a new HER2 x HER2 phase 3.
PD-(L)1 x VEGF bispecifics prove a big draw.
ADCs newly into human trials include Lilly's PTK7 and two bispecifics.
Bezuclastinib's registrational trial meets predefined success criteria, with a big spotlight on toxicity.
Some big deals in the second quarter have raised hopes that takeouts are back.
